• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

tjohn@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0003-3399-5342

Prof Tom John

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

342 Scholarly works
1 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Identifying High-Risk Stage I NSCLC: The Promises and Pitfalls of Tumor-Informed ctDNA
    DOI: 10.1016/j.jtho.2026.103706
  • 2026

    Journal article

    Navigating Evidence Standards: Stakeholder Perspectives on External Controls and Randomization in Cancer Trials.
    DOI: 10.1111/ajco.70120
  • 2026

    Journal article

    Impacts of Multidisciplinary Lung Cancer Meeting Presentation in a Clinical Quality Registry
    DOI: 10.1016/j.jtocrr.2026.100984
  • 2026

    Journal article

    Recent Advances in Combined Medical and Surgical Therapy for Resectable NSCLC
    DOI: 10.1002/resp.70238
  • 2026

    Journal article

    Treatment Timeliness in Extensive-Stage SCLC and Impact on Survival: A Registry-Based Observational Study
    DOI: 10.1016/j.jtocrr.2026.100978
  • 2026

    Journal article

    PP01.56: Final, 6-Year Outcomes with First-Line (1L) Nivolumab Plus Ipilimumab Plus Chemotherapy (N I C) in Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) from CheckMate 9LA
    DOI: 10.1016/j.jtho.2026.103799
  • 2025

    Research grants (ARC, NHMRC, MRFF)

    A Registry-Based Randomised Trial of Radiotherapy in Advanced Lung Cancer
Tom John

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Abstract LB105: Translational analyses from the randomized phase 3 DREAM3R trial: DuRvalumab with chEmotherapy as first line treAtment in advanced pleural Mesothelioma
    DOI: 10.1158/1538-7445.am2026-lb105
  • 2026

    Journal article

    Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group.
    DOI: 10.1016/j.jtho.2026.103696
  • 2026

    Journal article

    Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials
    DOI: 10.1016/j.lungcan.2025.108891
  • 2026

    Journal article

    Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee
    DOI: 10.1016/j.jtho.2026.103643

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224